Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Adaptimmune Therapeutics ( (ADAP) ) has issued an announcement.
On July 16, 2025, Adaptimmune Therapeutics plc entered into a settlement agreement with The University of Texas M.D. Anderson Cancer Center to resolve litigation related to a Strategic Alliance Agreement from 2016. The settlement, which involves financial payment obligations, is not expected to have a material adverse effect on Adaptimmune’s financial position or operations.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Spark’s Take on ADAP Stock
According to Spark, TipRanks’ AI Analyst, ADAP is a Neutral.
Adaptimmune Therapeutics is showing potential through revenue growth and operational achievements, particularly with TECELRA. However, significant financial risks due to persistent losses, negative equity, and a short cash runway are major concerns. Short-term technical indicators suggest some positive momentum, but the stock’s valuation remains unattractive due to ongoing losses.
To see Spark’s full report on ADAP stock, click here.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics is a biopharmaceutical company focused on the development of T-cell therapies for cancer treatment.
Average Trading Volume: 941,277
Technical Sentiment Signal: Sell
Current Market Cap: $70.39M
Learn more about ADAP stock on TipRanks’ Stock Analysis page.